

## **Product datasheet for TL315577**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **OLIG2 Human shRNA Plasmid Kit (Locus ID 10215)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** OLIG2 Human shRNA Plasmid Kit (Locus ID 10215)

**Locus ID:** 10215

Synonyms: BHLHB1; bHLHe19; OLIGO2; PRKCBP2; RACK17

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Lentiviral plasmids

**Components:** OLIG2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 10215).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 005806, NM 005806.1, NM 005806.2, NM 005806.3, BC047511, BC047511.1, BC034681,

BC036245, BC036275, NM 005806.4

UniProt ID: Q13516

Summary: This gene encodes a basic helix-loop-helix transcription factor which is expressed in

oligodendroglial tumors of the brain. The protein is an essential regulator of ventral

neuroectodermal progenitor cell fate. The gene is involved in a chromosomal translocation t(14;21)(q11.2;q22) associated with T-cell acute lymphoblastic leukemia. Its chromosomal location is within a region of chromosome 21 which has been suggested to play a role in

learning deficits associated with Down syndrome. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).